Recently, a multicenter, open-label, single-arm, phase 2, basket trial showed that the combination of dabrafenib (BRAF inhibitor) with trametinib (MEK inhibitor) has clinical efficacy against low- and high-grade gliomas [125]. Here, MAP2K7 is linked to glioma.